Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.57 |
| ▸ | DRD2 | P14416 | 3/20 | 0.52 |
| ▸ | DRD1 | P21728 | 3/20 | 0.52 |
| ▸ | DRD4 | P21917 | 3/20 | 0.52 |
| ▸ | DRD5 | P21918 | 3/20 | 0.52 |
| ▸ | DRD3 | P35462 | 3/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | OGA | O60502 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30561536 | 0.89 | MAOA (0.57) | HRH3DRD2DRD1DRD4DRD5 | |
| SCHEMBL1083820 | 0.89 | MAOA (0.57) | HRH3DRD2DRD1DRD4DRD5 | |
| SCHEMBL25043598 | 0.82 | DRD2 (0.48) | HRH3DRD2DRD1DRD4DRD5 | |
| SCHEMBL3719812 | 0.80 | KDM4E (0.54) | HRH3DRD2DRD1DRD4DRD5 | |
| SCHEMBL8259450 | 0.77 | HRH3 (0.50) | HRH3MAOAMAOBKCNH2ADRA1A | |
| SCHEMBL18033537 | 0.77 | HRH3 (0.50) | HRH3KCNH2ALDH1A1LMNACHRNA7 | |
| SCHEMBL22879105 | 0.77 | MAOA (0.53) | HRH3DRD2DRD1DRD4DRD5 | |
| SCHEMBL12230334 | 0.77 | MAPT (0.55) | HRH3MAOAMAOBCYP2D6TSHR | |
| SCHEMBL30589043 | 0.77 | MAOA (0.53) | HRH3DRD2DRD1DRD4DRD5 | |
| SCHEMBL12533128 | 0.77 | HRH3 (0.50) | HRH3DRD1DRD5MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228464-A9 | TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-12024507-B2 | Compounds as GLP-1R agonists | TERNS PHARMACEUTICALS, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12018017-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018017-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-11834436-B2 | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| EP-3621615-B1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20230174515-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174515-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230159512-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159512-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20120171126-A1 | NOVEL [3,2-c] HETEROARYL STEROIDS AS GLUCOCORTICOID RECEPTOR AGONISTS COMPOSITIONS AND USES THEREOF | PURAKKATTLE BIJU J (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120171126-A1 | NOVEL [3,2-c] HETEROARYL STEROIDS AS GLUCOCORTICOID RECEPTOR AGONISTS COMPOSITIONS AND USES THEREOF | PURAKKATTLE BIJU J (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | RADIUS HEALTH, INC. | 2012-01-05 | — | — | US | disclosed |
| US-20110182828-A1 | C20-C21 SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110182828-A1 | C20-C21 SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2011-07-28 | — | — | US | disclosed |
| US-7960412-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20110130385-A1 | Bicyclic Heterocylic Derivatives and Methods of Use | SCHERING CORPORATION | 2011-06-02 | — | — | US | disclosed |
| US-20110130385-A1 | Bicyclic Heterocylic Derivatives and Methods of Use | SCHERING CORPORATION | 2011-06-02 | — | — | US | disclosed |
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | RADIUS HEALTH, INC. | 2009-12-31 | — | — | US | disclosed |
| US-7612114-B2 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120171126-A1 | NOVEL [3,2-c] HETEROARYL STEROIDS AS GLUCOCORTICOID RECEPTOR AGONISTS COMPOSITIONS AND USES THEREOF | NR3C1, NR3C2, MC2R | HRH3 87/4885DRD2 1258/4885DRD1 1592/4885 |
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | ESR1, GPER1, ESR2 | HRH3 561/4885DRD2 2301/4885DRD1 1897/4885 |
| US-12024507-B2 | Compounds as GLP-1R agonists | GLP1R, GIPR, GCGR | HRH3 1573/4885DRD2 3615/4885DRD1 3310/4885 |
| US-12018017-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | BAD, CASP1, BAX | HRH3 4103/4885DRD2 4806/4885DRD1 4521/4885 |
| US-20230159512-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | HRH3 1519/4885DRD2 3607/4885DRD1 3327/4885 |
| US-20110130385-A1 | Bicyclic Heterocylic Derivatives and Methods of Use | GPR119, OXER1, INSR | HRH3 120/4885DRD2 628/4885DRD1 613/4885 |
| US-11834436-B2 | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | AIFM1, BAD, IRAK1 | HRH3 4358/4885DRD2 4874/4885DRD1 4705/4885 |
| US-20240228464-A9 | TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | AIFM1, BAD, IRAK1 | HRH3 4358/4885DRD2 4874/4885DRD1 4705/4885 |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | ESR1, GPER1, ESR2 | HRH3 583/4885DRD2 1993/4885DRD1 1838/4885 |
| US-20110182828-A1 | C20-C21 SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, MC2R, NR3C2 | HRH3 263/4885DRD2 1146/4885DRD1 1087/4885 |
| US-20230174515-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | BAD, CASP1, BAX | HRH3 4103/4885DRD2 4806/4885DRD1 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.